NCT03943927View on ClinicalTrials.gov

Preemptive Pharmacogenetic-guided Metoprolol Management for PostoperativeAtrial Fibrillation in Cardiac Surgery

NACompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

October 24, 2022

Study Completion Date

November 20, 2022

Conditions
Post-operative Atrial Fibrillation
Interventions
OTHER

Guided Metoprolol Management

"CYP2D6 Genotyping: Consented patients will have blood drawn for genotyping prior to surgery. Patients will be classified as poor metabolizers, intermediate metabolizers, extensive (normal) metabolizers, or ultrafast metabolizers.~Pharmacogenetic- Guided Metoprolol Management: A best practice advisory will be integrated into institutional clinical decision support systems for metoprolol dosing based on metabolic status of each patient."

Trial Locations (1)

37212

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt University Medical Center

OTHER

NCT03943927 - Preemptive Pharmacogenetic-guided Metoprolol Management for PostoperativeAtrial Fibrillation in Cardiac Surgery | Biotech Hunter | Biotech Hunter